Financial Performance - Aligos Therapeutics reported a net loss of 27.9 million in Q4 2023, resulting in a basic and diluted net loss per share of (5.50) in the prior year[8][20]. - For the full year 2024, the net loss was 87.7 million in 2023, with a basic and diluted net loss per share of (34.20) in 2023[9][20]. - Cash, cash equivalents, and investments totaled 135.7 million at the end of 2023; following a 105 million private placement completed in February 2025, funding is expected to last into the second half of 2026[7][5]. - General and administrative (G&A) expenses for Q4 2024 were 5.2 million, compared to 6.4 million in Q4 2023, with total G&A expenses for the year at 22.8 million, down from 30.6 million in 2023[12][13]. Research and Development - Research and development (R&D) expenses for Q4 2024 were 16.0 million, down from 22.3 million in Q4 2023, while total R&D expenses for the year were 70.3 million, slightly down from $73.0 million in 2023[10][11]. - Interim data from a Phase 1 study of ALG-000184 showed 100% sustained HBV DNA suppression in HBeAg-positive subjects by Week 48, with no viral breakthrough or known CAM resistant mutations observed[5][10]. - The Phase 2 clinical study for ALG-000184 is expected to begin in mid-2025, with the potential to replace standard care for chronic hepatitis B virus infection[2][5]. - ALG-055009 demonstrated statistically significant reductions in liver fat of up to 46.2% at Week 12, with 70% of subjects achieving a ≥30% relative reduction compared to baseline[5][12]. - Aligos commenced three additional clinical trials for ALG-097558 in 2024, with ongoing studies evaluating its efficacy in high-risk COVID-19 patients[6][12]. Funding and Development Strategy - The company is evaluating options for continued development funding, including potential out-licensing of its products[12][14].
Aligos Therapeutics(ALGS) - 2024 Q4 - Annual Results